King's College London

Research portal

Complement activation as a biomarker for Alzheimer's disease

Research output: Contribution to journalLiterature review

Original languageEnglish
Pages (from-to)204 - 215
Number of pages12
JournalImmunobiology
Volume217
Issue number2
DOIs
Publication statusPublished - Feb 2012

King's Authors

Abstract

There is increasing evidence from genetic, immunohistochemical, proteomic and epidemiological studies as well as in model systems that complement activation has an important role in the pathogenesis of Alzheimer's disease (AD). The complement cascade is an essential element of the innate immune response. In the brain complement proteins are integral components of amyloid plaques and complement activation occurs at the earliest stage of the disease. The complement cascade has been implicated as a protective mechanism in the clearance of amyloid, and in a causal role through chronic activation of the inflammatory response. In this review we discuss the potential for complement activation to act as a biomarker for AD at several stages in the disease process. An accurate biomarker that has sufficient predictive, diagnostic and prognostic value would provide a significant opportunity to develop and test for effective novel therapies in the treatment of AD. (C) 2011 Elsevier GmbH. All rights reserved.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454